Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase

• US 7,273,716 B2
• Filed: 10/22/2004
• Issued: 09/25/2007
• Est. Priority Date: 04/25/2003
• Status: Expired due to Term

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: McDermott, Martin
• Primary Examiner(s): Gitomer; Ralph
• Assistant Examiner(s): Shen; Bin
• Application Number:
  US10/970,389
• Publication Number:
  US 20050136397A1
• Time in Patent Office: 1,068 Days
• Field of Search: None
• US Class Current: 435/18
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12Q 1/44 involving esterase
• CPC Class Codes: G01N 2500/02 Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

By the present invention, enzymes responsible for prodrug activation are identified and utilized for the identification of candidate compounds as prodrugs. The present invention includes methods for identifying a candidate compound as a suitable prodrug as well as methods of screening candidate compounds for suitability as therapeutic agents.

Claims

1. A method for identifying a candidate compound as a suitable prodrug, comprising:

(a) providing a candidate compound having an esterified phosphonate group or an esterified carboxyl group;

(b) contacting the candidate compound with a purified extract that comprises GS-7340 ester hydrolase to produce one or more metabolite compounds; and

(c) identifying the candidate compound as a suitable prodrug if at least one of the one or more metabolite compounds has a phosphonic acid group instead of the esterified phosphonate group of the candidate compound, or a carboxylic acid group instead of the esterified carboxyl group of the candidate compound.

2. The method of claim 1, wherein said extract is obtained from peripheral blood mononuclear cells.

3. The method of claim 1, wherein said extract is a fully purified extract.

4. The method of claim 1, wherein said extract comprises an enzyme comprising SEQ ID NO:

1 or a fragent thereof.

5. The method of claim 1, wherein said providing step comprises providing a candidate compound formed by substituting a prototype compound.

6. The method of claim 1, further comprising (d) determining the intracellular persistence of the candidate compound.

7. The method of claim 1, further comprising (d) determining the intracellular persistence of at least one of the one or more metabolite compounds.

8. The method of claim 3, further comprising (d) determining the tissue selectivity of the candidate compound.

9. The method of claim 3, further comprising (d) determining the tissue selectivity of at least one of the one or more metabolite compounds.

10. A method for identifying a candidate compound as a suitable prodrug, comprising:

(a) providing a candidate compound formed by substituting an esterified phosphonate or an esterified carboxyl group into a prototype compound believed to have therapeutic activity;

(b) contacting the candidate compound with a purified extract of peripheral blood mononuclear cells that has GS-7340 ester hydrolase activity to produce one or more metabolite compounds; and

(c) identifying the candidate compound as a suitable prodrug if at least one of the one or more metabolite compounds has a phosphonic acid group instead of the esterified phosphonate group of the candidate compound, or a carboxylic acid group instead of the esterified carboxyl group of the candidate compound.

11. The method of claim 10, wherein said extract of peripheral blood mononuclear cells comprises an enzyme comprising SEQ ID NO:

1 or a fragment thereof.

12. The method of claim 10, wherein said contacting step comprises contacting the candidate compound with the extract in a cell-free environment.

13. The method of claim 10, wherein said contacting step comprises contacting the candidate compound with the extract in vitro.

14. The method of claim 10, wherein said contacting step comprises contacting the candidate compound with the extract in cell culture.

15. The method of claim 10, wherein said contacting step comprises contacting the candidate compound with the extract in a culture of peripheral blood mononuclear cells.

16. The method of claim 10, wherein said therapeutic activity is therapeutic activity against HIV.